Halozyme CTO Michael J. LaBarre retires effective March 17, 2025; no successor named

HALOZYME THERAPEUTICS, INC.

Michael J. LaBarre, SVP and Chief Technical Officer, retired effective March 17, 2025.
LaBarre notified the company of his decision on the same date.
He was recognized for contributions to the ENHANZE drug delivery technology.
No replacement has been announced for the CTO role.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Michael J. LaBarre

Senior Vice President, Chief Technical Officer

HALO · HALOZYME THERAPEUTICS, INC.

Effective: 2025-03-17
Filed: March 21, 2025, 7:59 PM ET

On March 17, 2025, Michael J. LaBarre, Senior Vice President, Chief Technical Officer of Halozyme Therapeutics, Inc. (the “Company”) notified the Company of his decision to retire from the Company, effective March 17, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Michael J. LaBarre retired as Senior Vice President, Chief Technical Officer at HALOZYME THERAPEUTICS, INC..

Action: retired
Role: Senior Vice President, Chief Technical Officer

Exact text from the filing

On March 17, 2025, Michael J. LaBarre, Senior Vice President, Chief Technical Officer of Halozyme Therapeutics, Inc. (the “Company”) notified the Company of his decision to retire from the Company, effective March 17, 2025.

View on SEC.gov

HALOZYME THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001159036-25-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.